Pharmaceutical and Medicinal Chemistry, Saarland University & Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Department of Drug Design and Optimization, Campus C2 3, 66123 Saarbrücken, Germany.
Eur J Med Chem. 2013 Jul;65:223-31. doi: 10.1016/j.ejmech.2013.04.060. Epub 2013 May 7.
Rising resistance against current antibiotics necessitates the development of antibacterial agents with alternative targets. The "switch region" of RNA polymerase (RNAP), addressed by the myxopyronins, could be such a novel target site. Based on a hit candidate discovered by virtual screening, a small library of 5-phenyl-3-ureidothiophene-2-carboxylic acids was synthesized resulting in compounds with increased RNAP inhibition. Hansch analysis revealed π (lipophilicity constant) and σ (Hammet substituent constant) of the substituents at the 5-phenyl moiety to be crucial for activity. The binding mode was proven by the targeted introduction of a moiety mimicking the enecarbamate side chain of myxopyronin into the hit compound, accompanied by enhanced RNAP inhibitory potency. The new compounds displayed good antibacterial activities against Gram positive bacteria and Gram negative Escherichia coli TolC and a reduced resistance frequency compared to the established antibiotic rifampicin.
当前抗生素的耐药性不断上升,这就需要开发具有替代靶点的抗菌药物。RNA 聚合酶(RNAP)的“开关区域”就是这样一个新的靶标位点,该区域可被粘菌素类药物所作用。基于虚拟筛选发现的一个命中候选物,我们合成了一个由 5-苯基-3-脲基噻吩-2-羧酸组成的小文库,得到了对 RNAP 抑制作用增强的化合物。Hansch 分析表明,5-苯基部分取代基的π(疏水性常数)和σ(Hammett 取代常数)对于活性至关重要。通过将模仿粘菌素烯碳酰胺侧链的部分靶向引入到命中化合物中,证明了结合模式,同时还提高了 RNAP 的抑制效力。与已有的抗生素利福平相比,新化合物对革兰氏阳性菌和革兰氏阴性菌大肠杆菌 TolC 具有良好的抗菌活性,并且耐药频率降低。